GlassScriptPhysician profile
Thomas Michael Brown
NPI 1386103281
$5,270.82
in general payments reported to CMS, 2019-2025
25 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $1,021 · 2023: $2,202 · 2024: $1,676 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,642 · Travel and Lodging: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,641.71 |
| Travel and Lodging | $465.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $1,275.02 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Abbvie INC. | $904.86 | 2021-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $602.76 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $304.11 | 2021-2024 | Winlevi, Absorica Ld |
| Ucb, INC. | $299.24 | 2023-2024 | Cimzia, Bimzelx |
| Lilly USA, LLC | $260.13 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $203.33 | 2023-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $202.31 | 2023-2024 | |
| Incyte Corporation | $159.38 | 2022-2024 | Opzelura |
| Dermavant Sciences, INC. | $140.93 | 2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $136.59 | 2024 | |
| Galderma Laboratories, L.P. | $132.33 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $119.51 | 2022 | |
| Arcutis Biotherapeutics, INC. | $107.18 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $84.70 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $77.12 | 2023-2025 | |
| Organogenesis INC. | $68.19 | 2023-2024 | Puraply |
| Pacira Pharmaceuticals Incorporated | $41.87 | 2025 | Exparel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.75 | 2024-2025 | Jublia, Cabtreo, Arazlo |
| Verrica Pharmaceuticals INC. | $24.87 | 2024 | Ycanth |
| Almirall LLC | $23.04 | 2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.29 | 2023 | Spevigo |
| Becton, Dickinson and Company | $16.54 | 2025 | Arista |
| Biofrontera INC. | $16.21 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mimedx Group, INC. | $15.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.